Dyne Therapeutics (DYN) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Telix Pharmaceuticals (TLX) has outperformed Dyne Therapeutics (DYN) over the past year, losing 6.1% versus a loss of 26.8%. Dyne Therapeutics is the larger company by market cap ($2.90 billion vs $2.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | TLX |
|---|---|---|
| Share price | $15.50 | $8.37 |
| Market cap | $2.90B | $2.84B |
| 1-day change | -3.31% | -3.90% |
| YTD return | -20.76% | +11.75% |
| 1-year return | -26.82% | -6.06% |
| 5-year return | +5.37% | — |
| P/E ratio (TTM) | — | 83.70 |
| EPS (TTM) | $-3.62 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $803.79M |
| Revenue growth (YoY) | — | +55.61% |
| Net income (latest FY) | $-446.21M | $-7.13M |
| Gross margin | — | 53.05% |
| Operating margin | — | 3.70% |
| Net margin | — | -0.89% |
| 52-week high | $27.31 | $13.11 |
| 52-week low | $14.00 | $6.28 |
| Distance from 52-week high | -43.23% | -36.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.48% | +134.89% |
| Average volume | 2.94M | 356.74K |
| Shares outstanding | 187.39M | 339.78M |
| Employees | 322 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLX has outperformed DYN by 20.8 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
DYN vs TLX FAQ
Which is bigger, Dyne Therapeutics or Telix Pharmaceuticals?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.90B compared with $2.84B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, DYN or TLX?
TLX returned -6.06% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.